Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin versus aspirin + fondaparinux before early invasive strategy in NSTEMI
2024-517229-18-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Non-ST-segment elevation myocardial infarction (NSTEMI) comparing Aspirin alone with Aspirin + fondaparinux (2 arms). Primary endpoint: Primary composite endpoint. Planned start Apr 2025; status: authorised.
02
Drugs
fondaparinuxaspirin
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on 2024-517229-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517229-18-00.